Actively Recruiting
A Study With CIT-013 in HS Patients
Led by Citryll BV · Updated on 2026-03-25
96
Participants Needed
24
Research Sites
86 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to learn if CIT-013 works to treat Hidradenitis Suppurativa in adults. It will also learn about the safety of CIT-013. The main questions it aims to answer are: Does CIT-013 lower the disease activity of HS patients? What medical problems do participants have when receiving CIT-013? Researchers will compare CIT-013 to a placebo (a look-alike substance that contains no drug) to see if CIT-013 works to treat the symptoms of HS. Participants will: Take receive 50 or 100 mg CIT-013 or placebo every other week for 12 weeks Visit the clinic once every 2 weeks for checkups and tests Keep monitor their symptoms during this period
CONDITIONS
Official Title
A Study With CIT-013 in HS Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female participants with HS of more than 6 months duration
- 18 years of age at screening visit
- HS lesions present in two or more distinct anatomic areas, one being Hurley Stage II or III
- Total abscess and inflammatory nodule count of 5 or more at screening and Day 1
- Inadequate response to oral antibiotics or recurrence after stopping, intolerance to, or contraindication for oral antibiotics
- Total draining tunnel count less than 20
You will not qualify if you...
- Participants for whom approved therapy with clinical benefit is indicated, available, and expected to be tolerated, or who choose standard of care treatment over the study drug
- Any current or recurrent significant skin condition in treatment area other than HS
- Prior treatment with recombinant therapeutic protein within 6 weeks before baseline
- Prior systemic therapy for HS within 28 days before baseline
- Prior intravenous anti-infective therapy within 14 days before baseline
- History of malignancy except non-melanoma skin cancer that has been excised and cured
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 24 locations
1
CA-01
Barrie, Canada
Actively Recruiting
2
CA-05
Calgary, Canada
Actively Recruiting
3
CA-02
London, Canada
Actively Recruiting
4
CA-04
Newmarket, Canada
Actively Recruiting
5
CA-03
Winnipeg, Canada
Actively Recruiting
6
DE-06
Bad Bentheim, Germany
Actively Recruiting
7
DE-01
Bochum, Germany
Actively Recruiting
8
DE-04
Dresden, Germany
Actively Recruiting
9
DE-02
Frankfurt, Germany
Actively Recruiting
10
DE-08
Kiel, Germany
Actively Recruiting
11
DE-03
Oldenburg, Germany
Not Yet Recruiting
12
Erasmus UMC
Rotterdam, Netherlands
Actively Recruiting
13
PL-03
Katowice, Poland
Actively Recruiting
14
PL-02
Lodz, Poland
Not Yet Recruiting
15
PL-01
Rzeszów, Poland
Actively Recruiting
16
PL-05
Wroclaw, Poland
Actively Recruiting
17
ES-05
Barcelona, Spain
Not Yet Recruiting
18
ES-04
Madrid, Spain
Not Yet Recruiting
19
ES-02
Santiago de Compostela, Spain
Not Yet Recruiting
20
ES-03
Seville, Spain
Not Yet Recruiting
21
ES-01
Valencia, Spain
Not Yet Recruiting
22
GB-02
Cardiff, United Kingdom
Not Yet Recruiting
23
GB-05
Chester, United Kingdom
Actively Recruiting
24
GB-04
London, United Kingdom
Actively Recruiting
Research Team
L
Leonie M Middelink
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here